Perrigo has obtained a valuable US Federal Court ruling that its generic version of Mucinex, a drug made by Reckitt Benckiser subsidiary Adams Respiratory Therapeutics, does not infringe on Adams’ patent.
The drug, a decongestant, is used to treat various respiratory conditions including asthma and bronchial infections.
Perrigo is now waiting for final U.S. Food and Drug Administration approval for the drug.
As the first company to successfully challenge the claim that patent term extension for Mucinex’s patent to 2020, Perrigo is entitiled to six months marketing exclusivity for generic version.
